Bristol-Myers and Halozyme to develop subcutaneous immuno-oncology drugs

Bristol-Myers Squibb has entered   a global collaboration and licence agreement to use Halozyme Therapeutics ’ Enhanze drug-delivery technology for the development of its subcutaneously administered immuno-oncology treatments.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news